Delta-8 THC Heart-Rate Tolerance Became Complete Before Other Tested Responses in Rats

A 1977 experiment in conscious rats found adaptation on pain-response, temperature and heart-rate measures during repeated delta-8 THC. Within the observed period, only heart-rate decreases reached complete tolerance.

Initial sensitivity differed by endpoint

Acute dosing produced dose-related tail-flick, cooling and cardiac-slowing responses. Heart rate was the most sensitive of the three measures under the protocol. Sensitivity to an initial dose and the completeness of later tolerance are separate properties.

Adaptation did not make every response disappear

The study described rapid tolerance on all three measures, yet complete tolerance within 13 days occurred only for cardiac slowing. That limits a broad claim that a repeated exposure history eliminated all tested effects. A smaller response also remains different from no response.

The experiment concerned delta-8 in male rats

The compound, species, exposure regimen and physiological measures constrain translation. Heart-rate normalization cannot be used as a proxy for pain-related adaptation, body temperature or complex behavior in a person. The study did not establish a human impairment threshold.

Interpreting the evidence

A tolerance description should specify both the initial sensitivity and how much the response changed over time. This experiment illustrates why complete adaptation on one measure cannot establish complete tolerance to a drug or safety of additional exposure.

Related reading: interpreting cannabis tolerance claims.

Research reference

Hine B; Toreelio M; Gershon S (1977). Analgesic, heart rate, and temperature effects of delta8-THC during acute and chronic administration to conscious rats. Pharmacology. PubMed research record.

This analysis draws on the supplied abstract.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

APD371 Maintained a Pain-Response Effect for Five Days in a Preclinical Development Study

A 2017 drug-discovery report described APD371, a selective CB2 agonist, maintaining its effect during a five-day rat osteoarthritis-pain protocol. That short preclinical finding is different from established long-term clinical efficacy. The report concerned selection of a development candidate The authors considered receptor efficacy, pharmacokinetics and pharmaceutical properties alongside an oral…

Spread the love

Read Article: APD371 Maintained a Pain-Response Effect for Five Days in a Preclinical Development Study

Two Biased CB2 Agonists Had Different Durability in a Rat Osteoarthritis Experiment

A 2021 rat study found sustained pain-response effects with JWH133 while another CB2 agonist lost efficacy after two days under its repeated-treatment protocol. Shared receptor targeting did not establish equal durability. The compounds were compared in a defined model The experiment used chemically induced osteoarthritis and measured pressure responses and…

Spread the love

Read Article: Two Biased CB2 Agonists Had Different Durability in a Rat Osteoarthritis Experiment

An Acute Cannabis Review Treated Neurocognitive Response as a Multi-Factor Question

A 2021 review argued that acute neurocognitive responses to cannabis vary with biological, pharmacological and exposure-related factors. A product label or use-frequency category alone cannot capture all the determinants discussed. The review considered interacting sources of variation It discussed brain-network activity, formulation, use frequency and differences between therapeutic and recreational…

Spread the love

Read Article: An Acute Cannabis Review Treated Neurocognitive Response as a Multi-Factor Question

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us